Search Results - Smits-Van der Graaf, C.

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    171P Carboplatin–paclitaxel bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with advanced NSCLC

    171P Carboplatin–paclitaxel bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with advanced NSCLC by Van Groningen, H., Timmer-Bonte, A., Van den Hurk, D., Dohmen, M., Smits-Van der Graaf, C., Van der Drift, M.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Carboplatin–paclitaxel bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with advanced NSCLC: 171P

    Carboplatin–paclitaxel bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with advanced NSCLC: 171P by Van Groningen, H, Timmer-Bonte, A, Van den Hurk, D, Dohmen, M, Smits-Van der Graaf, C, Van der Drift, M

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: